drug
RYBREVANT
updated 6mo agoby Janssen Biotech Inc
community read0 votes
🐶 often sniffed alongside
top 5all catalysts(0)
nothing on the calendar yet
News(10)
- J&J’s Rybrevant nets FDA approval in head and neck cancerThe FDA has granted accelerated approval to Johnson & Johnson’s cancer shot Rybrevant in head and neck cancer that’s come back after previous chemotherapy and immunotherapy. The approval is the fir…endpoints · 10d ago
- FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell CarcinomaThe U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and n…fda_press · 11d ago
- ArriVent collapses on disappointing lung cancer dataMore than half of the company’s value was wiped out by findings that appear to erase a chance to battle Johnson & Johnson and others for market share.biopharma_dive · 1mo ago
- ArriVent’s phase 3 lung cancer trial flops, sinking stockA phase 3 lung cancer study of ArriVent BioPharma’s EGFR inhibitor has missed its primary endpoint, sending the biotech’s stock down 57% in early trading on the Nasdaq.fiercebiotech · 1mo ago
- Rare EGFR mutation increases lung cancer risk 62 times in never smokersA rare inherited germline mutation was found to increase risk for lung cancer by 25 times, while smoking only increased risk by 4 times.fiercebiotech · 2mo ago
- Despite 3 patient deaths, Cullinan-Taiho plan FDA filing for lung cancer pill on survival benefitAnalysts believe Cullinan Therapeutics and Taiho Oncology can overcome the safety risks as zipalertinib “sets [a] new bar” for first-line treatment of a type of lung cancer. The candidate is alread…biospace · 2mo ago
- Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancerCullinan Therapeutics and Taiho Oncology unveiled phase 3 data showing survival improvements greater than Johnson & Johnson’s Rybrevant in patients with advanced non-small cell lung cancer in the f…fiercebiotech · 2mo ago
- New Taiho, Cullinan data heats up lung cancer drug battleThe findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.biopharma_dive · 3mo ago
- Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competitionTaiho Pharmaceutical and Cullinan Therapeutics’ cancer asset is already under FDA review in a later setting, with a decision expected by February.biospace · 3mo ago
- Taiho, Cullinan's lung cancer drug passes Phase 3 test, lining up Rybrevant contestTaiho Oncology and Cullinan Therapeutics said Wednesday that their next-gen EGFR inhibitor has cleared a registrational trial in the front-line setting of a genetically-defined type of lung cancer.…endpoints · 3mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that